These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25856827)

  • 21. Aflibercept for inflammatory choroidal neovascularization with persistent fluid on intravitreal ranibizumab therapy.
    Hernández-Martínez P; Dolz-Marco R; Alonso-Plasencia M; Abreu-Gonzalez R
    Graefes Arch Clin Exp Ophthalmol; 2014 Aug; 252(8):1337-9. PubMed ID: 24789465
    [No Abstract]   [Full Text] [Related]  

  • 22. Type 3 neovascularization: evolution, association with pigment epithelial detachment, and treatment response as revealed by spectral domain optical coherence tomography.
    Nagiel A; Sarraf D; Sadda SR; Spaide RF; Jung JJ; Bhavsar KV; Ameri H; Querques G; Freund KB
    Retina; 2015 Apr; 35(4):638-47. PubMed ID: 25650713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibrovascular pigment epithelial detachment is a risk factor for long-term visual decay in neovascular age-related macular degeneretion.
    Hoerster R; Muether PS; Sitnilska V; Kirchhof B; Fauser S
    Retina; 2014 Sep; 34(9):1767-73. PubMed ID: 24936942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term results of intravitreal ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography.
    Inoue M; Arakawa A; Yamane S; Kadonosono K
    Br J Ophthalmol; 2014 Jul; 98(7):956-60. PubMed ID: 24599418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration.
    Yonekawa Y; Andreoli C; Miller JB; Loewenstein JI; Sobrin L; Eliott D; Vavvas DG; Miller JW; Kim IK
    Am J Ophthalmol; 2013 Jul; 156(1):29-35.e2. PubMed ID: 23668679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alterations of vascular pigment epithelium detachments associated with age-related macular degeneration during upload with intravitreal ranibizumab.
    Wolf A; Rüping J; Neubauer AS; Mayer W; Ulbig M; Haritoglou C; Holz FG; Eter N; Kampik A
    Retina; 2013 Oct; 33(9):1843-9. PubMed ID: 23598795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.
    Wang X; Sawada T; Sawada O; Saishin Y; Liu P; Ohji M
    Am J Ophthalmol; 2014 Oct; 158(4):738-744.e1. PubMed ID: 24973606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Macular complications on the border of an inferior staphyloma associated with tilted disc syndrome.
    Nakanishi H; Tsujikawa A; Gotoh N; Hayashi H; Iwama D; Tamura H; Otani A; Yoshimura N
    Retina; 2008; 28(10):1493-501. PubMed ID: 18667957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial improvements when converting eyes with treatment-resistant exudative AMD to aflibercept are substantially diminished after increasing treatment intervals from 4 to 8 weeks.
    Jørstad ØK; Faber RT; Moe MC
    Acta Ophthalmol; 2015 Sep; 93(6):e510-1. PubMed ID: 25708506
    [No Abstract]   [Full Text] [Related]  

  • 30. Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications.
    Blaha GR; Brooks NO; Mackel CE; Pani A; Stewart AP; Price LL; Barouch FC; Chang J; Marx JL
    Retina; 2015 Mar; 35(3):577-81. PubMed ID: 25158942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
    Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F
    Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: one-year results.
    Mimoun G; Caillaux V; Querques G; Rothschild PR; Puche N; Souied EH
    Retina; 2013 Mar; 33(3):513-21. PubMed ID: 23400081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retinal pigment epithelial tear after intravitreal aflibercept for neovascular age-related macular degeneration.
    Sato T; Ooto S; Suzuki M; Spaide RF
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):87-90. PubMed ID: 25559517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravitreal aflibercept for choroidal neovascularisation complicating chronic central serous chorioretinopathy.
    Broadhead GK; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2015 Jun; 253(6):979-81. PubMed ID: 25547617
    [No Abstract]   [Full Text] [Related]  

  • 35. Branch retinal vein occlusion precipitated by compression between a major retinal artery and underlying optic disc drusen.
    Rothenbuehler SP; Maloca PM; Belmouhand M; Hamann S; Larsen M
    Acta Ophthalmol; 2021 Dec; 99(8):931-933. PubMed ID: 33880859
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T.
    Wykoff CC; Hariprasad SM
    Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):302-5. PubMed ID: 25835307
    [No Abstract]   [Full Text] [Related]  

  • 37. Dramatic resolution of choroidal neovascular abnormalities after single aflibercept injection following years of ranibizumab use.
    Chaikitmongkol V; Bressler NM
    JAMA Ophthalmol; 2013 Feb; 131(2):260-2. PubMed ID: 23411901
    [No Abstract]   [Full Text] [Related]  

  • 38. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
    Heier JS; Brown DM; Chong V; Korobelnik JF; Kaiser PK; Nguyen QD; Kirchhof B; Ho A; Ogura Y; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Groetzbach G; Sommerauer B; Sandbrink R; Simader C; Schmidt-Erfurth U;
    Ophthalmology; 2012 Dec; 119(12):2537-48. PubMed ID: 23084240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
    Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
    Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials.
    Domalpally A; Ip MS; Ehrlich JS
    Ophthalmology; 2015 Apr; 122(4):779-86. PubMed ID: 25601535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.